Clinical-stage Drug Candidates

Category Candidate Target Indication Preclinical IND Phase I Phase II Registration Trial Application Progress* and Upcoming Milestone Partner
Oncology and autoimmune diseases MIL62 Third-generation CD20
(ADCC-enhanced)
Follicular lymphoma(FL)
Relapsed/refractory
Phase III registration trial
(recruiting patients)
To submit NDA in 2024 2H
Follicular lymphoma(FL)
Untreated
To submit Phase III
registration trial application in 2021 2H
Diffuse large B-cell lymphoma(DLBCL)
Relapsed/refractory
Phase I/IIa trial (recruitment completed) Submitted Phase II
registration trial application in July 2021To submit NDA in 2023 2H
InnoCare
Diffuse large B-cell lymphoma(DLBCL)
Untreated
To submit Phase II/III trial application in 2021 2H InnoCare
Lupus nephritis (LN)
Phase Ib/II trial (recruiting patients)
Primary membranous nephropathy (PMN)
Phase Ib/II trial (recruiting patients)
Neuromyelitis optical spectrum disorder (NMOSD)
IND application approved for Phase Ib/III trial
Myasthenia gravis (MG)
Submitted IND application in July 2021
MIL93 Claudin 18.2
(ADCC-enhanced)
Claudin 18.2-positive gastric cancer, gastroesophageal junction cancer and pancreatic cancer
Phase I trial (recruiting patients)
To submit Phase III registration trial application in 2023 1H
MIL95 CD47 Lymphoma and advanced solid tumors
Phase I trial (recruiting patients) Keymed
MIL97 CD40 Metastatic pancreatic cancer and other solid tumors
Submitted IND application in May 2021 Phase I trial (Australia)
MBS301 HER2/HER2
(ADCC-enhanced bispecific antibody)
HER2-positive metastatic gastric cancer and other solid tumors
Phase I trial (recruiting patients)
Others MIL86 PCSK9 Hyperlipidemia
Phase II trial (recruiting patients)

OncologyAutoimmune diseasesPlanned trial to be initiatedOthers

Selected Preclinical Drug Candidates

Category Candidate Target Indication Preclinical IND Phase I Phase II Registration Trial Application Progress* and Upcoming Milestone Partner
Oncology and autoimmune diseases MIL98 LAG3 Melanoma, late-stage lymphoma and other late-stage malignant solid tumors
To submit IND application in 2022
MBS303 CD3-CD20 B cell non-Hodgkin lymphoma
To submit IND application in 2022
MBS304 CD3/Claudin 18.2 Gastric cancer and pancreatic cancer
To submit IND application in 2024
MBS307 PD-L1/CD40 Solid tumors
To submit IND application in 2023
MIL108 B7-H3
(ADCC-enhanced)
Non-small cell lung cancer and other solid tumors
To submit IND application in 2023 Biocytogen
MBS309 PD-1/IL-2 Solid tumors
To submit IND application in 2024